53rd EASD Annual Meeting (1)
Lisbon, Portugal, 11-Sep-17
Industry Symposium Boehringer/Lilly: Reducing cardiovascular mortality while considering the kidney in type 2 diabetes: can we do more?
Cosentino, MD, PhD F.
Poster Session 74: SGLT2 inhibitors and the heart
Deacon, MD C.F.
Oral Presentation 07: SGLT2 inhibitors: clinical utility
Sattar, Prof. Dr. N.
Effects on the incidence of cardiovascular events of the add-on of pioglitazone as compared with a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin: the TOSCA.IT study
Ceriello, Prof. A.
CANagliflozin cardiovascular Assessment Study (CANVAS)
Groop, Prof. P.-H.
Supported by Boehringer Ingelheim Pharma GmbH & Co. KG